%0 Journal Article
%T Cancer-Associated Thrombosis: Pathophysiology, Laboratory Assessment, and Current Guidelines.
%A Tsantes AG
%A Petrou E
%A Tsante KA
%A Sokou R
%A Frantzeskaki F
%A Domouchtsidou A
%A Chaldoupis AE
%A Fortis SP
%A Piovani D
%A Nikolopoulos GK
%A Iacovidou N
%A Bonovas S
%A Samonis G
%A Tsantes AE
%J Cancers (Basel)
%V 16
%N 11
%D 2024 May 30
%M 38893201
%F 6.575
%R 10.3390/cancers16112082
%X Dysregulated hemostasis in cancer patients is associated with various clinical conditions, from thromboembolic complications to disseminated intravascular coagulation. Despite the well-established association between cancer and thromboembolic complications, the mechanisms involved are not completely elucidated. There are several predisposing factors in cancer for increased thrombus generation, such as immobilization and chemotherapy. The term cancer-associated thrombosis (CAT) has been introduced to describe the close bidirectional relationship between cancer and thromboembolic events. Conventional coagulation tests (PT/aPTT) are more accurate in detecting a hypocoagulable rather than a hypercoagulable state; thus, their contribution to CAT management is limited. Traditionally, D-dimer levels have been the most common laboratory study for the evaluation of thrombotic risk. However, D-dimer levels only display a snapshot of the coagulation cascade, and they cannot provide a dynamic evaluation of evolving clot formation. Non-conventional assays, such as viscoelastic methods and microparticle formation are promising tools for the identification of patients at risk for developing CAT. Recent guidelines from the American Society of Clinical Oncology counsel against the estimation of thrombotic risk through a single test and recommend the use of scoring systems that take into account several risk factors. The present review outlines the current insights into the pathophysiological mechanisms of CAT and provides a comprehensive review of the latest advances in the laboratory assessment of CAT and the recent guidelines for the management of patients at risk for developing thromboembolic complications.